Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 13 clients • 21 examiners • 15 art units • 0 of 23 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
The firm operates in Biotechnology & Pharmaceuticals, with 1,292 career applications and 23 pending office actions. Its resolved allowance rate is 78.17%, indicating that the prosecution record includes a meaningful allowance outcome across a substantial application base.
The average is 3.13 office actions per allowance. For practitioners, that combination points to prosecution that commonly requires multiple rounds of examination before allowance, while the pending docket identifies continuing work that may require active response planning. The application volume provides context for interpreting the allowance rate, and the office-action average helps assess expected prosecution effort rather than focusing on allowance outcomes alone.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §101 + other | 1 (4%) |
| §103 only | 6 (26%) |
| §112 only | 4 (17%) |
| Double-patenting only | 2 (9%) |
| Double-patenting + other | 5 (22%) |
| Multi-statute (no §101) | 4 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 2 | 43.9% | +39.0% |
| RAMACHANDRAN, UMAMAHESWARI | 2 | 54.8% | +53.7% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
| HAWKINS, AMANDA SALATA | 1 | 15.4% | +40.9% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| CHENG, KAREN | 1 | 76.4% | +26.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | SALVOZA, M FRANCO G | 155d overdue |
| 18937105 | CARBAMOYL PHENYLALANINOL COMPOUNDS AND USES THEREOF | JACKSON, SHAWQUIA | — |
| 18819015 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | RAMACHANDRAN, UMAMAHESWARI | — |
| 18842454 | ENCAPSULATION OF HOP COMPOSITIONS | HAWKINS, AMANDA SALATA | — |
| 18711937 | METHOD TO DETECT RNA BIOMARKERS | BERTAGNA, ANGELA MARIE | — |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18918219 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | BORI, IBRAHIM D | — |
| 18894074 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PECKHAM, RICHARD GRANT | — |
| 18819015 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | RAMACHANDRAN, UMAMAHESWARI | — |
| 18842454 | ENCAPSULATION OF HOP COMPOSITIONS | HAWKINS, AMANDA SALATA | — |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | WHITE, DAWANNA SHAR-DAY | — |
| 18780629 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | RAMACHANDRAN, UMAMAHESWARI | — |
| 18721923 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | BOWLES, DAVID PAUL | — |
| 18711937 | METHOD TO DETECT RNA BIOMARKERS | BERTAGNA, ANGELA MARIE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Italfarmaco | 4 |
| Servier | 4 |
| Axsome Malta Ltd. | 2 |
| SK Group | 2 |
| Vernalis (R&D) Ltd. | 2 |
| Genetic S.p.A. | 2 |
| Dompé | 1 |
| Kalamazoo Holdings, Inc. | 1 |
| ESTEVE PHARMACEUTICALS, S.A. | 1 |
| Axsome Therapeutics | 1 |
| TUFTS MEDICAL CENTER, INC. | 1 |
| SEMENTIS LIMITED | 1 |
| NATIONAL UNIVERSITY OF IRELAND, GALWAY | 1 |
| Art Unit | Apps |
|---|---|
| 1627 | 5 |
| 1623 | 3 |
| 1629 | 2 |
| 1693 | 2 |
| 1626 | 1 |
| 1793 | 1 |
| 1654 | 1 |
| 1681 | 1 |
| 3786 | 1 |
| 1628 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18937105 | CARBAMOYL PHENYLALANINOL COMPOUNDS AND USES THEREOF | Axsome Malta Ltd. | JACKSON, SHAWQUIA | 1626 | §101Other | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18935803 | TREATMENT OF CATAPLEXY | SK Biopharmaceuticals Co., Ltd. | SHTERENGARTS, SAMANTHA L | 1623 | DP | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18918219 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | Dompé Farmaceutici S.p.A. | BORI, IBRAHIM D | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18894074 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Vernalis (R&D) Ltd. | PECKHAM, RICHARD GRANT | 1627 | §112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18819015 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | Axsome Malta Ltd. | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103§112Other | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18842454 | ENCAPSULATION OF HOP COMPOSITIONS | Kalamazoo Holdings, Inc. | HAWKINS, AMANDA SALATA | 1793 | §103§112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Vernalis (R&D) Ltd. | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18780629 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK Biopharmaceuticals Co., Ltd. | RAMACHANDRAN, UMAMAHESWARI | 1627 | DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18721923 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | Italfarmaco Spa | BOWLES, DAVID PAUL | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18711937 | METHOD TO DETECT RNA BIOMARKERS | Italfarmaco Spa | BERTAGNA, ANGELA MARIE | 1681 | §101§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18702363 | TRIMETAZIDINE SALTS | Les Laboratoires Servier | CHENG, KAREN | 1623 | §103 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | Esteve Pharmaceuticals, S.A. | BORI, IBRAHIM D | 1629 | §103DP | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | Axsome Therapeutics, Inc. | BREDEFELD, RACHAEL EVA | 3786 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | Genetic S.p.A. | SZNAIDMAN, MARCOS L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18579645 | PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE | Genetic S.p.A. | PIHONAK, SARAH | 1627 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18574801 | PROCESS FOR PREPARING DIOSMIN AND FLAVONOID FRACTION | Les Laboratoires Servier | BERRY, LAYLA D | 1693 | §112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18555103 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | Italfarmaco Spa | CHHAY, BONIRATH | 1645 | §103Other | Non-Final OA | 13d | Pending | Oct 12, 2023 |
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | Tufts Medical Center, Inc. | FISCHER, JOSEPH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | Sementis Limited | SALVOZA, M FRANCO G | 1672 | §103§112 | Final Rejection | 155d overdue | Pending | May 15, 2023 |
| 18040708 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | Italfarmaco S.p.A. | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Feb 06, 2023 |
| 18004468 | DIOSMIN PREPARATION METHOD | Les Laboratoires Servier | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17998368 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | Les Laboratoires Servier | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | — | Pending | Nov 10, 2022 |
| 16632453 | STENTED VALVE | National University Of Ireland, Galway | WOZNICKI, JACQUELINE | 3774 | §112 | Non-Final OA | 85d | Pending | Jan 20, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial78.2% of resolved applications prosecuted by The Firm Of Hueschen And Sage were allowed, across 1,292 applications in USPTO records.
3.13 office actions per allowed application on average.
23 pending office actions as of October 2026, for 13 clients, before 21 examiners in 15 art units.
